Alkermes (ALKS) said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD.
The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment.
ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added.
The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year.
Shares of the company were up over 7% in Monday's premarket activity.
Price: $46.50, Change: $+3.11, Percent Change: +7.17%